INVESTIGATION OF THE RELATIONSHIP BETWEEN CALPAIN AND HMGB1/TLR4/NF-KB SIGNALING PATHWAY IN MULTIPLE SCLEROSIS AND OTHER DEMYELINATING DISEASES

Firdevs Uluc,[1] Bihter Gokce Celik,[1] Seyda KARABORK,[2] Şule AYDIN TÜRKOĞLU,[3] Seyit Ali KAYIS,[3]

[1] Bolu Abant Izzet Baysal University, Institute of Health Sciences, Department of Interdisciplinary Neuroscience, Bolu

[2] Bolu Abant Izzet Baysal University, Faculty of Medicine, Department of Medical Microbiology, Bolu

[2] Bolu Abant Izzet Baysal University, Faculty of Medicine, Department of Neurology, Bolu

[3] Bolu Abant Izzet Baysal University, Faculty of Medicine, Department of Biostatistics and Medical Informatics, Bolu

ABSTRACT

Background: To develop more effective treatments for demyelinating diseases, it is essential to identify the associated signaling pathways and factors. The objective of this study was to investigate the possible correlation between Calpain-1 (CAPN1) and Calpain-2 (CAPN2) with the HMGB1/TLR4/NF-κB signaling pathway and to evaluate the influence of these proteins on Interleukin 17A (IL-17A) and Interleukin 37 (IL-37) cytokines in individuals with recently diagnosed untreated before Multiple Sclerosis (MS) and Neuromyelitis Optica Spectrum Disorder (NMOSD).

Methods: In this pilot study, a total of 73 newly diagnosed patients were recruited, including 36 with MS, 9 with NMOSD, and a control group composed of 28 individuals who had Pseudotumour cerebri (unhealthy control). To ensure accuracy and transparency, the demographic and clinical characteristics of all groups were meticulously described. ELISA technique was utilized to compare levels of CAPN1, CAPN2, HMGB1, TLR4, and NF-KB, as well as IL-17A and IL-37 cytokines, between the case groups and the unhealthy control group. The expectation from these findings is to provide valuable insights into the pathophysiological mechanisms of these neurological disorders, possibly opening the door to novel therapeutic perspectives.

Results: In patients with MS, the levels of CAPN1 were found to be higher than those in patients with NMOSD and PTS patients. Similarly, the level of CAPN2 was significantly higher in MS patients than in NMOSD patients and higher in PTS patients than in NMOSD patients. There were no notable differences in the levels of HMGB1, TLR4, NF-κB, IL-17A, and IL-37 between the groups. Age and gender did not significantly affect any of the parameters. In the MS group, both CAPN1 and CAPN2 showed positive correlation with HMGB1, TLR4, and NF-κB levels.

Conclusions: It may be suggested that CAPN1 may exhibit greater efficacy than CAPN2 during the initial stages of neuroinflammation. To obtain deeper and more guiding results of the varying levels of CAPN1 and CAPN2, and their relationship with the HMGB1/TLR4/NF-κB signaling pathway, it is advisable to conduct *in-vivo* and *in-vitro* prospective studies featuring CAPN1-specific inhibitors and larger study groups.

Keywords: Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder, Calpain-1, Calpain-2, High Mobility Group Box 1

1. Introduction

Multiple sclerosis (MS) is a chronic and inflammatory disease that affects the central nervous system (CNS). The degeneration and demyelination of neurons, which can lead to axonal loss and neuronal damage are the main characteristics of this disease (Yamout & Alroughani, 2018). This complex disease is known to cause a variety of symptoms that can affect the autonomic, motor, visual, and sensory systems. Over time, patients may experience episodes of acute neurological impairment or deterioration. MS is generally observed in young adults aged 20-40 years and affects approximately 2.3 million people worldwide. The prevalence ranges from 50-300 per 100000 people, with a higher incidence in women with a ratio of 1.5:1 to 2.5:1 (Thompson et al., 2018). The incidence and prevalence of MS are increasing worldwide, although the underlying causes of the disease remain not fully understood (Browne et al., 2014).

Neuromyelitis optica spectrum disorder (NMOSD) is a rare disease that primarily affects the spinal cord and optic nerve, as well as other parts of the brain. It was previously unclear whether NMOSD was a distinct disease or a more severe form of MS, but with the identification of the AQP4 water channel, NMOSD is now defined as a different disease from MS with its diagnostic criteria and treatments (Araki & Yamamura, 2017; Weinshenker & Wingerchuk, 2017).

Understanding the clinical manifestations and disease course of CNS demyelinating diseases requires knowledge of direct targets and signaling pathways, given their heterogeneous immunopathology (Popescu & Lucchinetti, 2012). To effectively treat these complex diseases, therapeutic agents must address both inflammation and neurodegeneration (W. Smith et al., 2017). The calpain system offers promise in this regard, with its ability to directly impact both aspects.

Calpains are a group of nonlysosomal cysteine proteases that are calcium-dependent and expressed in various cells of humans and other organisms. Their roles in various physiological and pathological processes are reported (Mahaman et al., 2019). The most extensively studied subtypes of the calpains are CAPN1 and CAPN2, which are also known as μ-calpain and m-calpain, respectively. These are widely expressed in most mammalian organs and cells; but are predominantly found in the brain (Sorimachi et al., 2012; Wang et al., 2018). Calpains are naturally occurring enzymes found in the cytosol as a pro-enzyme. In resting cells, the normal range of free Ca^{2+} concentrations is typically between 50-100 nM. When intracellular free Ca^{2+} concentrations increase, the pro-enzyme is activated and can also translocate upon contact with membrane-bound phospholipids for the degradation of membrane proteins (W. Smith et al., 2017). Within the normal range of intracellular free Ca^{2+} concentrations, calpain performs several important physiological functions including cytoskeletal reorganization, long-term potentiation, hormone processing, and protein turnover (Sorimachi et al., 2012; Wang et al., 2018). However, when intracellular free Ca^{2+} concentrations exceed the normal threshold, uncontrolled and prolonged calpain activation may occur (Baraban et al., 2018; Yamashima, 2016).

HMGB1 is a protein that exists in all mammalian cells and does not bind to histone DNA. Its primary structure consists of two homologous HMG box domains, A box, and B box, as well as a C-terminal acidic tail (Sternberg et al., 2016; Štros, 2010). This protein is present in astrocytes, neurons, and microglia in both the CNS and peripheral nervous system, as well as in the cytoplasm and extracellular spaces of neurons and Schwann cells (Fang et al., 2012). Furthermore, it has a considerable expression in regions of brain neurogenesis, such as the dentate gyrus and olfactory bulb (Guazzi et al., 2003). HMGB1 has a critical role as a DNA chaperone in the nucleus during normal physiological conditions. In macrophages, it is actively secreted or passively released from damaged or dead cells. Additionally, it has a

pivotal function as a cytokine-inducing early inflammatory response. HMGB1 carries out its physiological role by binding to various membrane receptors, including receptors for advanced glycation end products (RAGE) and toll-like receptors (TLRs), which initiate the signaling cascade. When HMGB1 interacts with TLR4, it triggers the upregulation of NF-κB and results in the release of proinflammatory cytokines, chemokines, and enzymes (Li et al., 2018; Trotta et al., 2014). Notably, the release of pro-inflammatory cytokines by macrophages in response to HMGB1 is dependent on the presence of TLR4 (Harris et al., 2012).

The molecular mechanisms that are responsible for inflammation and immune response in the development of MS and other demyelinating diseases are not yet fully understood. It is crucial to determine these mechanisms to develop effective treatment options for this disease. Although there are various treatment alternatives available for MS and NMOSD patients in the active phase, their short-term and limited efficacy, side effects, and inability to prevent relapses make it necessary to develop advanced treatment options that are specific to each disease. According to a recent study, patients with Systemic Sclerosis, an autoimmune disease, showed a correlation between calpain and HMGB1 levels (Zheng et al., 2020). This study builds on that idea, suggesting that CAPNs and HMGB1, also known as platelet-derived microparticles, may be related to MS and other demyelinating diseases. By examining the relationship between CAPN1 and CAPN2 and HMGB1 levels, as well as the differences in protein levels between these two pathologies, we hope to develop more effective and targeted treatment options for MS and NMOSD. Our research aims to contribute to the literature on calpains and HMGB1 in demyelinating diseases from a unique perspective, with the potential to inform treatment strategies targeting both inflammation and demyelination.

2. Methods

2.1.Subjects

The study received ethical approval from the Bolu Abant Izzet Baysal University (BAIBU) Local Ethical Committee under decision number 2021/305 on April 1st, 2022, and followed the guidelines outlined in the Helsinki Declaration. The study utilized cerebrospinal fluid samples from seventy-three patients who were diagnosed between February 2021 and May 2023 at the Neurology outpatient clinic of the BAIBU Training and Research Hospital in Bolu, Türkiye. The case group included thirty-six patients diagnosed with MS according to McDonald's criteria (McDonald et al., 2001) and nine patients diagnosed with NMOSD according to International NMO diagnostic panel criteria (Wingerchuk et al., 2015). To obtain control CSF samples, healthy individuals were not available, so we recruited CSF samples from twenty-eight patients diagnosed with PTS according to Dandy criteria (Dandy, 1937). As there is limited information about PTS in terms of inflammation, it serves as a suitable unhealthy control, similar to non-inflammatory diseases. For the MS group, we selected cases from the RRMS subtype and for the NMOSD group, cases were selected from the ON and TM subtypes. Primary PTS patients were selected for the PTS group. CSF samples were collected via the Lumbar Puncture method and stored at -80°C. The cases with another autoimmune disease did not enroll to avoid cross-reactivity.

2.2.Quantification of Protein Levels with ELISA

In this study, the human ELISA kits (Sunred Biological Technology Co., Ltd in Shanghai, China) were utilized. Before conducting the assays, all CSF samples were carefully thawed at temperatures between 2-8°C and allowed to reach room temperature for 30 minutes. The tests were executed following the supplier company's provided instructions.

2.3. Statistical Analysis

Statistical analysis was conducted using SPSS version 22.0 for Windows (SPSS Inc., Chicago, IL, USA). GraphPad Prism version 9.5.1 and R Project version 4.3.1 were used to

generate graphical representations. Percentage distributions were used for categorical-demographic data of the cases and controls. The Kolmogorov-Smirnov test was used for determining the distribution characteristics of variables that showed continuous variation. One-way ANOVA was used to compare normally distributed data in multiple groups, while the t-test was used for pairwise post-hoc comparison (and Bonferroni correction was performed). Kruskal-Wallis test was used for non-normally distributed data, the Mann-Whitney U test was used to compare different groups, and the Bonferroni correction was applied. In descriptive statistics, mean ± standard deviation values were provided for normally distributed characteristics, while median and minimum-maximum values were given for non-normally distributed characteristics. To detect the relationship between variables, the Pearson correlation test was performed. $p < 0.05$ was accepted as the statistical significance level.

3. Results

3.1. Demographic and clinical features of patients

Upon analyzing the gender distribution of participants, 86.1% of the patients in the MS group were female and 13.9% were male. 66.7% of the patients were female and 33.3% were male in the NMOSD group. In the unhealthy control group, the percentage of male and female patients was 17.9% and 82.1%, respectively. All participants were aged between 18-65 years. When comparing the mean age of participants based on gender, no statistically significant difference was observed between the mean age of females and males (p= 0.306). The results showed a significant difference in demyelinating diseases among individuals aged 18-25 years and older compared to PTS (p=0.025). The results showed a significant difference in demyelinating diseases among individuals aged 18-25 years and older compared to PTS (p=0.025). Gender did not affect age at disease onset (p=1.000), with equal distribution of early/late onset cases in men and women, as well as MS and NMOSD. In terms of EDSS scores, no significant difference was observed between the MS and NMOSD groups,

however, women had a higher EDSS score than men (p=0.008). Any significant correlation in EDSS scores and CAPN1 and CAPN2 levels in the demyelinating disease groups was not observed. In Table 1, the demographic and clinical features of the groups was shown.

Table 1. Demographic and clinical characteristics

		Demyelinating Disorders		Control
		MS	NMOSD	PTS
Number of patients (n)		36	9	28
Gender (male/female) (n (%))				
	Male	5 (13.9)	3 (33.3)	5 (17.9)
	Female	31 (86.1)*	6 (66.7)*	23 (82.1)*
Mean Age (mean±SD)		32.0±9.33		39.3±11.1
Age Groups (n (%))				
18-25 years		20 (83.3)*		4 (16.7)
26-39 years		13 (54.2)		11 (45.8)
40+ years		12 (48)		13 (52.0)
EDSS (mean±SD)		1.06±0.2	1.22±0.4	---
IgG Index (Median (Min/Max))				
Early Onset (≤ 35 years)		0.77 (0.45/3.14)		
Late Onset (> 35 years)		0.70 (0.19/6.81)		
Oligoclonal band (n)				
Type 1 Negative		7		17**
Type 2 Positive		28**		1
Type 3/4/5 Positive		5		1

EDSS: Expanded Disability Status Scale, IgG: Immunoglobulin G, SD: Standard Deviation
*: $p < 0.05$, **: $p < 0.001$, p-value obtained via *ki-square* test

3.2. Assessment of ELISA Results

3.2.1. CAPN1 and CAPN2 levels

Significant differences were found in the levels of CSF CAPN1 between the MS group and both the PTS group (p=0.001) and the NMOSD group (p=0.002) (Fig. 1). The levels of CAPN1 and CAPN2 did not differ by gender across the three groups (p=1.000). Additionally, there was a moderate, positive correlation between the levels of CAPN1 and CAPN2 across all groups (r=0.425, p=0.001). The levels of CAPN1 and CAPN2 also showed a moderate, positive correlation in the MS group (r=0.543, p=0.001) (Fig. 2). No significant differences in the levels of CAPN1 and CAPN2 based on age or gender were detected.



Fig. 1. The levels of CAPN1 and CAPN2 in CSF. Horizontal lines indicate mean values. Asterisks indicate differences using one-way ANOVA with Bonferroni multiple comparisons post-hoc test. (*p < 0.05, ** p < 0.001).



Fig. 2. Correlation between CAPN1 and CAPN2 in MS group. Scatter plots show bivariate normal distributions with varying Pearson correlation coefficients (r).

3.2.2. HMGB1, TLR4 and NF-κB levels

No significant differences were found in the CSF levels of HMGB1, TLR4, and NF-κB among the groups (Fig.3).



Fig. 3. CSF levels of (a) HMGB1, (b) TLR4 and (c) NF-κB. Horizontal lines indicate mean values.

3.2.3. IL-17A and IL-37 Levels

No significant difference was found in IL-17A and IL-37 levels among the groups. However, a moderate positive correlation (p=0.001, r=0.472) was found between these two cytokines (Fig. 4.).



Fig. 4. (a) (b) CSF levels of IL-17A and IL-37. Horizontal lines indicate mean values.

3.2.4. Relationship between CAPN1 and CAPN2 with HMGB1/TLR4/NF-κB Signaling Pathway

In the MS patients, CAPN1 and HMGB1 showed a moderate and positive correlation. Also, TLR4 and NF-κB showed a weak and positive correlation with CAPN1. The correlation matrix, which illustrates the relationship between CAPN1 and HMGB1/TLR4/NF-κB signaling pathway in the MS group, is presented in Fig. 5.



Fig. 5. Matrix scatter plot (below the diagonal), distributional properties (diagonal) and corresponding correlation matrix (above the diagonal) for CAPN1 and HMGB1/TLR4/NF-κB signaling pathway's variables

In individuals with MS, a slight positive correlation was noted between CAPN2 and HMGB1, as well as between CAPN2 and TLR4. However, there was no significant correlation found between NF-κB and CAPN2. Figure 6 displays a correlation matrix illustrating the relationship between CAPN2 and the HMGB1/TLR4/NF-κB signaling pathway in the MS group. Notably, neither CAPN1 nor CAPN2 showed any significant correlation with the HMGB1/TLR4/NF-κB signaling pathway in the NMOSD and PTS groups.



Fig.6. Matrix scatter plot (below the diagonal), distributional properties (diagonal) and corresponding correlation matrix (above the diagonal) for CAPN1 and HMGB1/TLR4/NF-κB signaling pathway's variables

3.2.5. Relationship between CAPN1 and CAPN2 with IL-17A and IL-37

Although no correlation was found between CAPN1 and IL-17A, a positive correlation was discovered between IL-37 and CAPN1 (r=0.327, p=0.005). Additionally, positive correlation was observed between CAPN2 and IL-17A and IL-37 (r=0.356, p=0.002, and r=0.295, p=0.011 respectively). In the MS group, there was a moderate positive correlation between CAPN1 and IL17A (r=0.457, p=0.005) and a weak positive correlation between CAPN1 and IL-37 (r=0.340, p=0.016). Similarly, a moderate positive correlation was observed between CAPN2 and IL-17A (r=0.490, p=0.002) and between CAPN2 and IL-37 (r=0.361, p=0.030) in the MS group. However, no significant correlation was found between IL-17A and IL-37 with CAPN1 and CAPN2 in the NMOSD and PTS groups.

4. Discussion

This is the first study to compare the levels of CAPN1 and CAPN2 in demyelinating diseases, and their relationship with the HMGB1/TLR4/NF-KB signaling pathway. Upon

analysis, it was discovered that patients with MS, NMOSD, and PTS had higher CAPN1 levels than CAPN2. CAPN1 activation is usually associated with neuroprotection, while CAPN2 activation is tied to neurodegeneration (Baudry, 2019). Previous clinical and experimental research has focused mainly on CAPN2 activity in the pathogenesis of MS and NMOSD. CAPN1 is present in the cytoplasm of macrophages, microglia, and astrocytes. Although CAPN2 is primarily found within these cells, it also exists in certain neuronal cytoplasm regions outside of plaques. A recent study examining CAPN1 and CAPN2 expression levels in acute MS lesions found a noteworthy boost in CAPN1 expression relating to axon damage, along with a similar increase in CAPN2. While CAPN1 is present in significantly greater quantities than CAPN2 within acute plaques, both proteins see increases in conjunction with axon damage in these areas. Moreover, research has shown that both calpains exhibit similar levels of expression, even in regions where axon damage is minimal (Baudry et al., 2013; Baudry & Bi, 2016; Gan-Or & Rouleau, 2016; Wang et al., 2020). While previous studies have reported the protective effects of CAPN1, an experimental study found that CAPN1 activation is elevated during the early stages of ALS disease. This increase may be linked to intracellular molecular mechanisms that seek to safeguard neurons from cell death and irreversible damage. According to researchers (Stifanese et al., 2014), an increase in CAPN1 may prevent certain cellular events from occurring, which could otherwise have negative effects. Our study found higher levels of CAPN1 than CAPN2 in newly diagnosed MS patients during the early stages of the disease, possibly indicating a similar protective mechanism to what was observed in the ALS study. In MS, there is typically a preclinical period of two years, during which neuroinflammation is observed before diagnosis. During this period, both pro-inflammatory and anti-inflammatory cytokines increase (Tzartos et al., 2008). The increase in the levels of CSF CAPN1 in newly diagnosed patients during the early stages could be related to the regulation of cytokine activity, thus it might potentially play a

protective role in the neuroinflammation process. However, more research is necessary to determine how CAPN1 and CAPN2 levels change in the later stages of the disease and after treatment before making definitive statements. No significant differences in CAPN1 and CAPN2 levels between groups based on gender or age. However, previous research has shown that CAPN1 levels are higher in female rodents compared to males (Cerghet et al., 2006). It's possible that the small patient groups in our study may have limited our ability to detect gender differences in calpain levels, and gender may interact with other factors to impact CAPN1 and CAPN2 levels. It is possible that gender could be a confounding factor in terms of both CAPN1 and CAPN2 levels and could show an effect with other factors. Our evaluation revealed that CAPN1 and CAPN2 levels were not affected by age. However, experimental studies have shown that calpain expression is higher in young rats than in adult rats (Ibrahim et al., 1994). Additionally, another study suggested that there may be a relationship between aging and calpain activity in the brain, indicating that the regional heterogeneity of calpain levels in the brain parallels age-related deterioration (Banay-Schwartz et al., 1994). In MS and NMOSD, advanced age at disease onset may lead to a poor prognosis. Therefore, our findings suggest that further investigation is required to determine the impact of age on calpain levels. The absence of discernible age-related disparities in our study sample may be attributed to its limited size. Therefore, more extensive research with larger sample sizes will be necessary to establish the correlation between age and calpain levels.

The levels of HMGB1, a marker for inflammation, did not differ significantly among the three groups. Previous research has indicated that NMOSD patients have higher levels of serum HMGB1 compared to MS patients (K.-C. Wang et al., 2012). A study involving CSF samples reported no significant difference in HMGB1 levels between NMO and MS patients (H. Wang et al., 2013). Our findings were consistent with these previous studies, as we found

no significant difference in HMGB1 levels between MS and NMOSD patients. TLR4 and NF-κB levels, both parameters related to HMGB1 activity, were not different between the groups. However, our results did reveal a positive correlation between HMGB1 and TLR4 and NF-κB, which is in line with the mechanism of action of HMGB1.

To evaluate the neuroinflammation activity of CAPN1, CAPN2, and HMGB1, we analyzed the levels of IL-17A and IL-37, which are known to play a role in the neuroinflammation process. Across all three groups, we observed higher levels of IL-37 compared to IL-17A. While previous studies have suggested that IL-17A may be elevated in the cerebrospinal fluid of MS patients, its detection in serum during different stages of the disease remains controversial. Some studies have explored the role of IL-17A in MS pathogenesis, while others suggest that its detection alone may not be sufficient to determine inflammatory activity (Edwards et al., 2013; Lebrun et al., 2016). Our study found no correlation between IL-17A and EDSS score, indicating a lack of direct effect concerning disease activity. In contrast, recent research has shown promise for IL-37 in treating neuroinflammatory diseases, but there is limited data on its efficacy for MS and NMOSD. Previous studies have reported increased IL-37 levels in serum and CSF during acute inflammation (Farrokhi et al., 2015; Li et al., 2013), which is consistent with our findings of high IL-37 levels during the relapse period. These results may suggest that the increased level of anti-inflammatory IL-37 during the preclinical period of MS is reflective of the cytokine/chemokine profile shaping disease activity.

5. Conclusions

In this study, CSF samples utilized were obtained from patients during their relapse period. to compare the levels of CAPN1 and CAPN2, as well as HMGB1 during remission, future prospective follow-up studies must be conducted. The concept of dichotomy exists concerning the distinct roles of CAPN1 and CAPN2 in neuroinflammation and

neurodegeneration, presenting a crucial area of focus for researchers in the development of more precise and effective therapeutic interventions. It is imperative to explore this topic in-depth to gain a better understanding of the mechanistic basis of these diseases and devise targeted treatment strategies to alleviate the symptoms of neuroinflammation and neurodegeneration. It would be advantageous to perform research employing calpain inhibitors, particularly in vitro, to ascertain whether the elevated CAPN1 level we identified in our results is influenced by a neuroprotective mechanism as explained in existing literature, or by a characteristic that contributes to neurodegeneration. Conducting studies using specific inhibitors may produce more conclusive outcomes regarding the direct impact of these calpain species on disease activity and their association with the HMGB1/TLR4/NF-κB signaling pathway.

Credit authorship contribution statement

Firdevs Uluç: Conceptualization, Methodology, Investigation, Formal analysis, Visualization, Writing – original draft, Writing – review & editing. **Bihter Gökçe Çelik**: Conceptualization, Writing – review & editing. **Şeyda Karabörk**: Writing – review & editing. **Şule Aydın Türkoğlu**: Writing – review & editing, Validation, Supervision. **Seyit Ali Kayış**: Formal analysis, Validation.

Declaration of Competing Interest

The authors declare that they have no conflicts of interest.

Funding

This study was funded by Bolu Abant Izzet Baysal University Scientific Research Projects grant no 2022.08.32.1579.

References

Araki M, Yamamura T. Neuromyelitis optica spectrum disorders: Emerging therapies. Clin Exp Neuroimmunol. 2017;8(2):107–16.

Banay-Schwartz M, DeGuzman T, Palkovits M, Lajtha A. Calpain activity in adult and aged human brain regions. Neurochem Res. 1994;19(5):563–7.

Baraban M, Koudelka S, Lyons DA. Ca 2+ activity signatures of myelin sheath formation and growth in vivo. Nat Neurosci. 2018;21(1):19–23.

Baudry M, Bi X. Calpain-1 and calpain-2: The yin and yang of synaptic plasticity and neurodegeneration. Trends Neurosci. 2016;39(4):235–45.

Baudry M, Chou MM, Bi X. Targeting calpain in synaptic plasticity. Expert Opin Ther Targets. 2013;17(5):579–92.

Baudry M. Calpain-1 and calpain-2 in the brain: Dr. Jekill and Mr Hyde? Curr Neuropharmacol. 2019;17(9):823–9.

Browne P, Chandraratna D, Angood C, Tremlett H, Baker C, Taylor BV, et al. Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity. Neurology. 2014;83(11):1022–4.

Cerghet M, Skoff RP, Bessert D, Zhang Z, Mullins C, Ghandour MS. Proliferation and death of oligodendrocytes and myelin proteins are differentially regulated in male and female rodents. J Neurosci. 2006;26(5):1439–47.

Dandy WE. Intracranial pressure without brain tumor: Diagnosis and treatment. Ann Surg. 1937;106(4):492–513.

Edwards LJ, Sharrack B, Ismail A, Tench CR, Gran B, Dhungana S, et al. Increased levels of interleukins 2 and 17 in the cerebrospinal fluid of patients with idiopathic intracranial hypertension. Am J Clin Exp Immunol. 2013;2(3):234–44.

Fang P, Schachner M, Shen Y-Q. HMGB1 in development and diseases of the central nervous system. Mol Neurobiol. 2012;45(3):499–506.

Farrokhi M, Rezaei A, Amani-Beni A, Etemadifar M, Kouchaki E, Zahedi A. Increased serum level of IL-37 in patients with multiple sclerosis and neuromyelitis optica. Acta Neurol Belg. 2015;115(4):609–14.

Friedman DI, Liu GT, Digre KB. Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. Neurology. 2013;81(13):1159–65.

Gan-Or Z, Rouleau GA. Calpain 1 in neurodegeneration: a therapeutic target? Lancet Neurol. 2016;15(11):1118.

Guazzi S, Strangio A, Franzi AT, Bianchi ME. HMGB1, an architectural chromatin protein, and extracellular signaling factor, has a spatially and temporally restricted expression pattern in mouse brain. Gene Expr Patterns. 2003;3(1):29–33.

Harris HE, Andersson U, Pisetsky DS. HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. Nat Rev Rheumatol. 2012;8(4):195–202.

Ibrahim M, Upreti RK, Kidwai AM. Calpain from rat intestinal epithelial cells: age-dependent dynamics during cell differentiation. Mol Cell Biochem. 1994;131(1):49–59.

Lebrun C, Cohen M, Pignolet B, Seitz-Polski B, Bucciarelli F, Benzaken S, et al. Interleukin 17 alone is not a discriminant biomarker in early demyelinating spectrum disorders. J Neurol Sci. 016;368:334–6.

Li C, Zhao P, Sun X, Che Y, Jiang Y. Elevated levels of cerebrospinal fluid and plasma interleukin-37 in patients with Guillain-Barré Syndrome. Mediators Inflamm. 2013;2013:1–9.

Li J, Shi J, Sun Y, Zheng F. Glycyrrhizin, a potential drug for autoimmune encephalomyelitis by inhibiting high-mobility group box 1. DNA Cell Biol. 2018;37(12):941–6.

Mahaman YAR, Huang F, Kessete Afewerky H, Maibouge TMS, Ghose B, Wang X. Involvement of calpain in the neuropathogenesis of Alzheimer's disease. Med Res Rev. 2019;39(2):608–30.

McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50(1):121–7.

Popescu BFG, Lucchinetti CF. Pathology of demyelinating diseases. Annu Rev Pathol. 2012;7(1):185–217.

Sorimachi H, Mamitsuka H, Ono Y. Understanding the substrate specificity of conventional calpains. Biol Chem. 2012;393(9):853–71.

Sternberg Z, Sternberg D, Chichelli T, Drake A, Patel N, Kolb C, et al. High-mobility group box 1 in multiple sclerosis. Immunol Res. 2016;64(2):385–91.

Stifanese R, Averna M, De Tullio R, Pedrazzi M, Milanese M, Bonifacino T, et al. Role of calpain-1 in the early phase of experimental ALS. Arch Biochem Biophys. 2014 Nov 15; 562:1–8.

Stros M. HMGB proteins: interactions with DNA and chromatin. Biochim Biophys Acta. 2010;1799(1–2):101–13.

Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. Lancet. 2018;391(10130):1622–36.

Trotta T, Porro C, Calvello R, Panaro MA. Biological role of Toll-like receptor-4 in the brain. J Neuroimmunol. 2014;268(1–2):1–12.

Tzartos JS, Friese MA, Craner MJ, Palace J, Newcombe J, Esiri MM, et al. Interleukin-17 production in the central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol. 2008;172 (1):146–55.

W. Smith A, K. Ray S, Das A, Nozaki K, Rohrer B, L. Banik N. Calpain inhibition as a possible new therapeutic target in multiple sclerosis. AIMS Mol Sci. 2017;4(4):446–62.

W. Smith A, K. Ray S, Das A, Nozaki K, Rohrer B, L. Banik N. Calpain inhibition as a possible new therapeutic target in multiple sclerosis. AIMS Mol Sci. 2017;4(4):446–62.

Wang H, Wang K, Wang C, Xu F, Zhong X, Qiu W, et al. Cerebrospinal fluid high-mobility group box protein 1 in neuromyelitis optica and multiple sclerosis. Neuroimmunomodulation. 2013;20(2):113–8.

Wang K-C, Tsai C-P, Lee C-L, Chen S-Y, Chin L-T, Chen S-J. Elevated plasma high-mobility group box 1 protein is a potential marker for neuromyelitis optica. Neuroscience. 2012; 226:510–6.

Wang Y, Bi X, Baudry M. Calpain-2 as a therapeutic target for acute neuronal injury. Expert Opin Ther Targets. 2018;22(1):19–29.

Wang Y, Liu Y, Bi X, Baudry M. Calpain-1 and Calpain-2 in the Brain: New Evidence for a Critical Role of Calpain-2 in Neuronal Death. Cells. 2020;9(12).

Weinshenker BG, Wingerchuk DM. Neuromyelitis Spectrum Disorders. Mayo Clin Proc. 2017;92(4):663–79.

Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177–89.

Yamashima T. Can “calpain-cathepsin hypothesis” explain Alzheimer neuronal death? Ageing Res Rev. 2016; 32:169–79.

Yamout BI, Alroughani R. Multiple sclerosis. Semin Neurol. 2018;38(2):212–25.

Zheng C, Chen J, Chu F, Zhu J, Jin T. Inflammatory role of TLR-MyD88 signaling in multiple sclerosis. Front Mol Neurosci. 2019; 12:314.